SRTD Biotech
SRTD Biotech develops selectively expressed RNA (seRNA) therapeutics that remain inactive in healthy cells and activate only upon detecting disease-specific RNA markers. The platform combines modular seRNA constructs with proprietary fusogenic lipid nanoparticles for organ-targeted delivery, enabling cell-selective treatment for oncology, severe liver diseases, and autoimmune conditions.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Artificial Intelligence
Funding
Raised to date
€31.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $34.3Macross 1 round
AABILVMRNB€31.5M · Seed
Announced Nov 2026
Disclosed cumulative: $34.3M
Founders
Founder details are not available yet.
Product
Problem
Many severe diseases still lack effective treatment. Where therapies exist, they often hit healthy cells too, and side effects limit the dose patients can receive. This off-target toxicity constrains treatment efficacy for diseases with high unmet medical need.
Solution
SRTD Biotech provides a platform of selectively expressed RNA (seRNA) constructs that are delivered inactive and switch on only when they detect a disease-specific RNA inside the target cell. An antisense sensor recognizes the disease marker, which removes a blocker from an internal ribosome entry site and allows the therapeutic effector to be expressed—only in diseased cells. The sensor and effector are modular, so exchanging one creates a new therapy. The company's proprietary fusogenic lipid nanoparticles (fLNPs) deliver seRNA directly into the cytosol of target organs, including the liver and beyond. This approach enables potent therapies that spare healthy tissue, allowing effectors that would be too toxic if expressed systemically.
Target Audience
Primary customers are biopharmaceutical companies developing targeted therapies for oncology, severe liver diseases, and autoimmune conditions, as well as clinical researchers seeking cell-selective RNA therapeutics.
Features
- Modular seRNA architecture with interchangeable sensor and effector domains, enabling rapid generation of new therapeutic candidates
- Antisense sensor-based gating mechanism that keeps the construct silent in healthy cells and clears it within hours
- Fusogenic lipid nanoparticles that merge with the cell membrane for direct cytosolic release, avoiding endosomal degradation
- Organ-specific targeting via particle composition, with demonstrated hepatic and extrahepatic delivery
- Dual therapeutic modes: cell depletion for oncology and metabolic restoration for fibrotic liver disease
- AI-powered lab-in-the-loop discovery platform for identifying disease-specific RNA markers and optimizing construct selectivity and potency